Novel Strategies For The Early Identification Provention And Treatment Of The Microvascular Complications Of Diabetes
Funder
National Health and Medical Research Council
Funding Amount
$4,715,000.00
Summary
Despite recent advances, approximately one third of subjects with type 1 diabetes develop kidney disease and similar proportion develop vision-threatening eye disease. Indeed, in many instances eye and kidney disease occur in the same individual. The central aim of this proposed Special Program is the exploration of mechanisms that lead to the development and progression of these devastating complications of type 1 diabetes with a particular focus on novel strategies, directly applicable to man, ....Despite recent advances, approximately one third of subjects with type 1 diabetes develop kidney disease and similar proportion develop vision-threatening eye disease. Indeed, in many instances eye and kidney disease occur in the same individual. The central aim of this proposed Special Program is the exploration of mechanisms that lead to the development and progression of these devastating complications of type 1 diabetes with a particular focus on novel strategies, directly applicable to man, for their prevention and treatment. Participants in Special Program include both established diabetes researchers and investigators from other areas of academia (blood vessel biology and applied genetics). Strong interrelationships between the various investigators and their departments already exist and will be further consolidated with continued collaboration, sharing a combination of models, novel interventions and complex genetic techniques that would not be possible outside of a large collaborative framework. In addition to academic collaboration, interactions with industry-based drug discovery programs is also an important component in developing new treatment strategies for diabetic kidney and eye disease. The Special Program will thus consist of a range of studies of direct relevance to diabetic kidney and diabetic eye disease in humans. It is expected that these studies will lead to new strategies for the prevention, treatment and even the reversal of long term complications of diabetes.Read moreRead less
Roles Of Enzymes Of The Dipeptidyl Peptidase Gene Family In Human Liver
Funder
National Health and Medical Research Council
Funding Amount
$79,750.00
Summary
Chronic liver diseases, particularly those caused by autoimmune disease, alcohol and Hepatitis B and C virus infection, are major causes of morbidity and mortality in our community. They are characterised by progressive scarring of the liver which finally leads to liver failure and the need in many cases for organ transplantation. Each year 15,000 Australians become infected, probably for life, with hepatitis C virus. Unless more effective treatments are developed approximately 20% of these infe ....Chronic liver diseases, particularly those caused by autoimmune disease, alcohol and Hepatitis B and C virus infection, are major causes of morbidity and mortality in our community. They are characterised by progressive scarring of the liver which finally leads to liver failure and the need in many cases for organ transplantation. Each year 15,000 Australians become infected, probably for life, with hepatitis C virus. Unless more effective treatments are developed approximately 20% of these infections will progress to liver failure or liver cancer within 30 years. Diabetes afflicts 150 million people, and 90% have Type 2 diabetes. We request funding of our research on a family of enzymes highly prospective as targets for novel therapies for these diseases. We are internationally recognised experts on this enzyme family and on liver disease. The prototype member of this enzyme family, dipeptidyl peptidase (DP) IV, is being targeted by novel drugs that are in phase III clinical trials for Type 2 diabetes. Family member fibroblast activation protein (FAP) is targeted by novel anti-cancer drugs We were first to clone and lodge patent applications for two new enzymes of this family, DP8 and DP9. Our research proposal would lead to determination of whether FAP, DP8 and-or DP9 are valuable targets for novel liver disease therapeutics and facilitate generating the development of such therapeutics by a more thorough understanding of the activities and roles of these enzymes Completion of this project will greatly increase our understanding of these enzymes and their roles in chronic liver injury. This work can potentially lead to the development of specific inhibitors of enzyme function designed to relieve liver damage.Read moreRead less